PROGNOSTIC SIGNIFICANT OF ASXL1 MUTATIONS IN MYELODYSPLASTIC SYNDROMES
(Abstract release date: 05/19/16)
EHA Library. Wang S. 06/09/16; 132764; E1215
Dr. Shao-Yuan Wang
Contributions
Contributions
Abstract
Abstract: E1215
Type: Eposter Presentation
Background
Although additional sex comb-like 1 (ASXL1) gene mutations have long been reported in Myelodyspastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML), the prognostic significance has been controversial.
Aims
Perform a meta-analysis to study impact of ASXL1 mutations on patients with MDS and CMML.
Methods
The identified articles were retrieved from some common databases. We extracted hazard ratios (HRs) for overall survival (OS) and leukemic-free survival (LFS) and P value of some clinical parameters, which compared AXSL1 mutations and those without from the available studies. Each individual HR and P value was used to calculate the pooled HR and P value.
Results
6 studies covering 1689 patients were selected for this meta-analysis. The pooled HRs for OS and LFS were 1.45(95%CI, 1.24-1.70) and 2.20(95%CI, 1.53-3.17), respectively. When considering CMML patients alone the HR for OS was 1.50(95%CI, 1.18-1.90) . Additional, ASXL1 mutations were more frequently found in male (P=0.008), older (P=0.019) and patients with lower platelets (P=0.009) or hemoglobin level (P=0.0015) and associated with other mutations such as EZH2, IDH1/2, RUNX1 and TET2.
Conclusion
ASXL1 mutations were associated with poor prognosis in MDS, which may contribute to risk stratification and prognostic assessment in the disease.
Session topic: E-poster
Keyword(s): Mutation, Myelodysplasia, Prognosis
Type: Eposter Presentation
Background
Although additional sex comb-like 1 (ASXL1) gene mutations have long been reported in Myelodyspastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML), the prognostic significance has been controversial.
Aims
Perform a meta-analysis to study impact of ASXL1 mutations on patients with MDS and CMML.
Methods
The identified articles were retrieved from some common databases. We extracted hazard ratios (HRs) for overall survival (OS) and leukemic-free survival (LFS) and P value of some clinical parameters, which compared AXSL1 mutations and those without from the available studies. Each individual HR and P value was used to calculate the pooled HR and P value.
Results
6 studies covering 1689 patients were selected for this meta-analysis. The pooled HRs for OS and LFS were 1.45(95%CI, 1.24-1.70) and 2.20(95%CI, 1.53-3.17), respectively. When considering CMML patients alone the HR for OS was 1.50(95%CI, 1.18-1.90) . Additional, ASXL1 mutations were more frequently found in male (P=0.008), older (P=0.019) and patients with lower platelets (P=0.009) or hemoglobin level (P=0.0015) and associated with other mutations such as EZH2, IDH1/2, RUNX1 and TET2.
Conclusion
ASXL1 mutations were associated with poor prognosis in MDS, which may contribute to risk stratification and prognostic assessment in the disease.
Session topic: E-poster
Keyword(s): Mutation, Myelodysplasia, Prognosis
Abstract: E1215
Type: Eposter Presentation
Background
Although additional sex comb-like 1 (ASXL1) gene mutations have long been reported in Myelodyspastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML), the prognostic significance has been controversial.
Aims
Perform a meta-analysis to study impact of ASXL1 mutations on patients with MDS and CMML.
Methods
The identified articles were retrieved from some common databases. We extracted hazard ratios (HRs) for overall survival (OS) and leukemic-free survival (LFS) and P value of some clinical parameters, which compared AXSL1 mutations and those without from the available studies. Each individual HR and P value was used to calculate the pooled HR and P value.
Results
6 studies covering 1689 patients were selected for this meta-analysis. The pooled HRs for OS and LFS were 1.45(95%CI, 1.24-1.70) and 2.20(95%CI, 1.53-3.17), respectively. When considering CMML patients alone the HR for OS was 1.50(95%CI, 1.18-1.90) . Additional, ASXL1 mutations were more frequently found in male (P=0.008), older (P=0.019) and patients with lower platelets (P=0.009) or hemoglobin level (P=0.0015) and associated with other mutations such as EZH2, IDH1/2, RUNX1 and TET2.
Conclusion
ASXL1 mutations were associated with poor prognosis in MDS, which may contribute to risk stratification and prognostic assessment in the disease.
Session topic: E-poster
Keyword(s): Mutation, Myelodysplasia, Prognosis
Type: Eposter Presentation
Background
Although additional sex comb-like 1 (ASXL1) gene mutations have long been reported in Myelodyspastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML), the prognostic significance has been controversial.
Aims
Perform a meta-analysis to study impact of ASXL1 mutations on patients with MDS and CMML.
Methods
The identified articles were retrieved from some common databases. We extracted hazard ratios (HRs) for overall survival (OS) and leukemic-free survival (LFS) and P value of some clinical parameters, which compared AXSL1 mutations and those without from the available studies. Each individual HR and P value was used to calculate the pooled HR and P value.
Results
6 studies covering 1689 patients were selected for this meta-analysis. The pooled HRs for OS and LFS were 1.45(95%CI, 1.24-1.70) and 2.20(95%CI, 1.53-3.17), respectively. When considering CMML patients alone the HR for OS was 1.50(95%CI, 1.18-1.90) . Additional, ASXL1 mutations were more frequently found in male (P=0.008), older (P=0.019) and patients with lower platelets (P=0.009) or hemoglobin level (P=0.0015) and associated with other mutations such as EZH2, IDH1/2, RUNX1 and TET2.
Conclusion
ASXL1 mutations were associated with poor prognosis in MDS, which may contribute to risk stratification and prognostic assessment in the disease.
Session topic: E-poster
Keyword(s): Mutation, Myelodysplasia, Prognosis
{{ help_message }}
{{filter}}